As a new investor to CU6 this research is amazing, thank you for sharing.
is there answers to your following questions?
1. "Diagnostic agents could receive quick approval - do they need a phase 3 trial?"
Is it possible they could seek approval off early data than recruit the full 383 patients? FDA meeting sounded positive.
2. "Are there any trials pending to be completed between now and Q2 2024?
The Secure Cu64/67 SAR-bisPSMA trial entering Cohort 3 out of 4, 44 patient and obviously results look extremely good thus far even on a single dose of 8GBq, could we assume cohort 4 will be reported well before Q2?
I notice TLX were a $2b Market cap at the time of approval of Illucix, valued on the positive P3 results, however had licensed from Elli Lilly, impacting some of the upside.
Research/Valuation, page-7
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.67 |
Change
0.070(1.52%) |
Mkt cap ! $1.452B | |||
| Open | High | Low | Value | Volume |
| $4.68 | $4.95 | $4.60 | $9.186M | 1.917M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2515 | $4.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.70 | 25000 | 2 |
View Market Depth
| Last trade - 16.10pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$4.67 |
Change
0.070 ( 2.33 %) |
||||
| Open | High | Low | Volume | ||
| $4.67 | $4.95 | $4.60 | 138383 | ||
| Last updated 15.59pm 30/05/2024 ? | |||||
| CU6 (ASX) Chart |